Loading company…
Ucello Therapeutics develops universal CAR-T cell therapies for malignant tumors.
Founded in 2020, Ucello Therapeutics researches and produces universal CAR-T cell therapies. Its technologies include cell culture, gene editing, and plasmid virus, and its CBT-X20 platform has been used to develop cell therapy products for malignant tumors. The company is based in Chengdu, China, and is at Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in